GMP Certified / Ceftriaxone Sodium and Sulbactam Sodium for Injection 1.5g

• Quality Standard: USP, Bp
• Usage Mode: Injection
• Factory Certified: GMP
• Transport Package: Carton
• Specification: 1.5g
• Trademark: Sinolead
• Model NO.: Powder for injection
• Origin: China
• Production Capacity: 100000ctns Per Month

Product Description

Generic Name	Ceftriaxone Sodium and Sulbactam Sodium for Injection
Strength	1.5 g
Packing	10 vials /box
Origin	China

 

 

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Ceftriaxone Sodium and Sulbactam Sodium for Injection

Character:
This product is a compound preparation, its components are ceftriaxone sodium and sulbactam sodium (ceftriaxone and sulbactam labeled ratio is 2:1). There is no auxiliary material in the prescription.

Indications:
This product is used only for the treatment of moderate and severe infections caused by β-lactamase-producing bacteria resistant to ceftriaxone monotherapy and sensitive to this compound.
1. Lower respiratory tract infection: pneumonia, acute onset of chronic bronchitis, acute bronchitis, pulmonary abscess and other lung infections caused by β-lactamase producing Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Klebsiella, Haemophilus influenzae and other sensitive bacteria.
2. Acute bacterial otitis media: caused by β-lactamase producing Streptococcus pneumoniae, Haemophilus influenzae, Moraxella and other sensitive bacteria.
3. Skin and skin soft tissue infections: caused by β-lactamase producing Staphylococcus aureus, Streptococcus epidermidis, Streptococcus pyogenes and other streptococcus, Escherichia coli, Enterobacter, Klebsiella, Pseudomonas aeruginosa, anaerobic bacteria and other sensitive bacteria.
4, urethral infection: by β-lactamase producing Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and other sensitive bacteria caused.
5, simple gonorrhea: caused by the production of beta-lactamase gonococcus.
6, pelvic inflammation: caused by the production of β-lactamase gonococcus.
7. Bacterial septicemia: Bacteremia and septicemia caused by β-lactamase producing Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella and other sensitive bacteria.
8. Bone and/or joint infection: caused by β-lactamase producing Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Clostridium, Proteus mirabilis and other sensitive bacteria.
9, intraperitoneal infection: by β-lactamase producing Escherichia coli, Klebsiella, fragile bacteroides, clostridium and other sensitive bacteria caused.
In order to delay the progression of resistance and maintain the efficacy of this product, this product is used only for the treatment of moderate to severe infections caused by β-lactamase-producing bacteria identified or strongly suspected to be resistant to ceftriaxone monotherapy and sensitive to this compound. Appropriate specimens should be collected for microbiological examination to isolate and identify the pathogen causing the infection and to determine its sensitivity. While waiting for test results, empiric treatment can be used. After obtaining culture and drug sensitivity results, antimicrobial therapy should be selected or adjusted based on the results of microbiological examination.

Drug interaction:
Due to the compatibility of this product with more contraindicated drugs, it is recommended to be administered alone.
1, cephalosporin intravenous infusion with erythromycin, tetracycline, amphotericin B, vasoactive drugs (m-hydroxyamine, norepinephrine, etc.), phenytoin sodium, chlorpromazine, isopropanol, vitamin B group, vitamin C, etc., will appear turbiness. Prosulfanilamide, aspirin, intomethacin, butazone, sulfanilamide can reduce the excretion of sulbactam sodium from the kidney, so the combination of these drugs with this product can increase the blood concentration, prolong the excretion time, and may increase the toxicity.
2. Sulbactam sodium should not be combined with disulfiram (acetaldehyde dehydrogenase inhibitor), and disulfiram-like reactions may occur in individual patients when drinking alcohol or taking alcohol-containing drugs during the application of this product, so drinking alcohol and taking alcohol-containing drugs should be avoided during the application of this product and within a few days after taking the drug.
3. This product is incompatibility with aminopteridine, vancomycin, fluconazole and aminoglycoside antibiotics.
4, this product can not be added to Hartmann's and Ringer's calcium containing solution.

Pharmacology and toxicology:
This product is a compound preparation composed of ceftriaxone sodium and sulbactam sodium (the labeled ratio of ceftriaxone sodium to sulbactam sodium is 2:1).
Ceftriaxone sodium is the third generation of cephalosporin antibiotics, which can achieve bactericidal effect by interfering with the biosynthesis of bacterial cell wall. It has strong activity against enterobacteriaceae. The MIC90 for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, citrobacter flaudiensis, Proteus indole-positive, Prusdenobacteria and Serratia ranged from 0.12 to 0.25mg/L. It has strong antibacterial effect on Haemophilus influenzae, Neisseria gonorrhoeae and Neisseria meningitidis, and has good effect on hemolytic streptococcus and pneumococcus. The MIC for Staphylococcus aureus is 2 to 4mg/L. The sensitivity of Enterobacter cloacae, Acinetobacter and pseudomonas aeruginosa to this product is poor. Methicillin-resistant staphylococcus and enterococcus are resistant to this product. Most Bacteroides fragilis are resistant to this product.
Sulbactam sodium is a β-lactamase inhibitor, which has the advantages of low toxicity, good stability and strong enzyme inhibition activity. Sulbactam sodium can irreversibly inhibit most β-lactamases (especially ultra-broad spectrum β-lactamases). Except Neisseraceae and acinetobacter, sulbactam sodium had no antibacterial activity against other bacteria.
When ceftriaxone sodium is combined with sulbactam sodium, sulbactam sodium can effectively inhibit the activity of β-lactamase and protect ceftriaxone sodium from being hydrolyzed or cracked by β-lactamase in human body, so that the MIC of infected bacteria resistant to ceftriaxone sodium due to enzyme production can be reduced to the sensitive range.

Storage:
Keep in a cold (no more than 20ºC) and dry place.